BRPI0415836A - composto, métodos para a modulação da atividade de receptor de quimocina em um mamìfero, e para o tratamento, a melhoria, o controle ou a redução do risco de uma doença ou distúrbio inflamatório e imunorregulatório, e de artrite reumatóide, composição farmacêutica - Google Patents

composto, métodos para a modulação da atividade de receptor de quimocina em um mamìfero, e para o tratamento, a melhoria, o controle ou a redução do risco de uma doença ou distúrbio inflamatório e imunorregulatório, e de artrite reumatóide, composição farmacêutica

Info

Publication number
BRPI0415836A
BRPI0415836A BRPI0415836-9A BRPI0415836A BRPI0415836A BR PI0415836 A BRPI0415836 A BR PI0415836A BR PI0415836 A BRPI0415836 A BR PI0415836A BR PI0415836 A BRPI0415836 A BR PI0415836A
Authority
BR
Brazil
Prior art keywords
ameliorating
mammal
disorder
inflammatory
risk
Prior art date
Application number
BRPI0415836-9A
Other languages
English (en)
Inventor
Mark Jensen
Robert Larsen
Daniel Richard Sidler
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BRPI0415836A publication Critical patent/BRPI0415836A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

"COMPOSTO, MéTODOS PARA A MODULAçãO DA ATIVIDADE DE RECEPTOR DE QUIMOCINA EM UM MAMìFERO, E PARA O TRATAMENTO, A MELHORIA, O CONTROLE OU A REDUçãO DO RISCO DE UMA DOENçA OU DISTúRBIO INFLAMATóRIO E IMUNORREGULATóRIO, E DE ARTRITE REUMATóIDE, COMPOSIçãO FARMACêUTICA". A presente invenção proporciona uma sintese eficiente para a preparação de ((1R,3S)-3-isopropil-3-{¢3-(trifluorometil)-7,8-di-hidro-1,6-naftiridin-6(5 H)-il!-carbonil}-ciclo-pentil)¢(3S,4S)-3-metóxi-tetra-hidro-2H-piran-4-il!- amina e seu sal de succinato. A presente invenção adicionalmente proporciona uma síntese eficiente para a preparação de intermediários (3R)-3-metóxi-tetra-hidro-4H-piran-4-ona; ácido (1S,4S)-4-(2,5-dimetil-1H-pirrol-1-il)-1-isopropil-ciclo-pent-2-eno-1-car boxílico; e 3-(trifluorometil)-5,6,7,8-tetra-hidro- 1,6-naftiridina; e para a preparação do precursor (3S,4S)-N-((1S,4S)-4-isopropil-4-{¢3-trifluorometil)-7,8-di-hidro-1,6-naft iridin-6(5H)il!-carbonil}-ciclo-pent-2-en-1-il)-3-metóxi-tetra-hidro-2H-pir an-4-amina. A invenção adicionalmente reside nas propriedades superiores do sal de succinato de ((1R,3S)-3-isopropil-3-{¢3-(trifluorometil)-7,8-di-hidro-1,6-naftiridin-6(5 H)-il!-carbonil}-ciclo-pentil)¢(3S,4S)-3-metóxi-tetra-hidro-2H-piran-4-il!- amina.
BRPI0415836-9A 2003-10-27 2004-10-25 composto, métodos para a modulação da atividade de receptor de quimocina em um mamìfero, e para o tratamento, a melhoria, o controle ou a redução do risco de uma doença ou distúrbio inflamatório e imunorregulatório, e de artrite reumatóide, composição farmacêutica BRPI0415836A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51473503P 2003-10-27 2003-10-27
PCT/US2004/035069 WO2005044264A1 (en) 2003-10-27 2004-10-25 Ccr-2 antagonist salt

Publications (1)

Publication Number Publication Date
BRPI0415836A true BRPI0415836A (pt) 2007-01-02

Family

ID=34572774

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415836-9A BRPI0415836A (pt) 2003-10-27 2004-10-25 composto, métodos para a modulação da atividade de receptor de quimocina em um mamìfero, e para o tratamento, a melhoria, o controle ou a redução do risco de uma doença ou distúrbio inflamatório e imunorregulatório, e de artrite reumatóide, composição farmacêutica

Country Status (21)

Country Link
US (1) US7473696B2 (pt)
EP (1) EP1682135B1 (pt)
JP (1) JP4542550B2 (pt)
KR (1) KR20060101476A (pt)
CN (1) CN1870998B (pt)
AT (1) ATE517622T1 (pt)
AU (1) AU2004287416C1 (pt)
BR (1) BRPI0415836A (pt)
CA (1) CA2543201C (pt)
CO (1) CO5690606A2 (pt)
EC (1) ECSP066524A (pt)
IL (1) IL175009A0 (pt)
IS (1) IS8400A (pt)
MA (1) MA28104A1 (pt)
MX (1) MXPA06004647A (pt)
NO (1) NO20062377L (pt)
NZ (1) NZ546447A (pt)
RU (1) RU2317295C1 (pt)
UA (1) UA81365C2 (pt)
WO (1) WO2005044264A1 (pt)
ZA (1) ZA200602752B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060030582A1 (en) * 2002-04-29 2006-02-09 Demartino Julie Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
JO2479B1 (en) 2002-04-29 2009-01-20 ميرك شارب اند دوم ليمتد Rates for the activity of the chemokine receptor of tetrahydrobranyl cycloneptil tetrahydrobredo predine
EP1565436B1 (en) 2002-11-27 2012-04-25 Incyte Corporation 3-aminopyrrolidine derivatives as modulators of chemokine receptors
CN1826334A (zh) * 2003-03-18 2006-08-30 麦克公司 趋化因子受体活性的四氢吡喃基环戊基杂环酰胺调节剂
AR045875A1 (es) * 2003-10-27 2005-11-16 Merck & Co Inc Procedimiento para la preparacion del antagonista ccr-2
KR20080052683A (ko) 2003-12-18 2008-06-11 인사이트 코포레이션 케모킨 수용체의 조절제로서의3-사이클로알킬아미노피롤리딘 유도체
BRPI0510665A (pt) 2004-05-11 2007-12-04 Incyte Corp 3-(4-heteroarilcicloexilamino) ciclopentano-carboxiamidas como moduladores de receptores de quimiocinas
GB0413605D0 (en) * 2004-06-17 2004-07-21 Addex Pharmaceuticals Sa Novel compounds
MXPA06014672A (es) 2004-06-28 2007-03-26 Incyte Corp 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas.
WO2006004741A2 (en) 2004-06-28 2006-01-12 Incyte Corporation 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
CN101534824A (zh) 2006-11-17 2009-09-16 艾博特公司 作为化学活素受体拮抗剂的氨基吡咯烷
US20090076065A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched mk-0812
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
WO2012125663A2 (en) * 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Cyclohexane substituted amino cyclopentane derivatives as useful ccr2 antagonists
WO2013149376A1 (en) 2012-04-02 2013-10-10 Abbott Laboratories Chemokine receptor antagonists
HK1216233A1 (zh) 2013-02-28 2016-10-28 参天制药株式会社 含有四氢吡喃基氨基环戊基羰基四氢吡啶并吡啶衍生物作为有效成分的眼後段疾病的预防或治疗剂
DK3297438T3 (da) 2015-05-21 2022-01-17 Chemocentryx Inc Ccr2-modulatorer
CA3293051A1 (en) 2017-09-25 2026-03-02 Chemocentryx, Inc. Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
CN112105353B (zh) 2018-01-08 2024-04-19 凯莫森特里克斯股份有限公司 Ccr2拮抗剂治疗实体瘤的方法
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
CN112341350A (zh) * 2020-10-19 2021-02-09 江苏威奇达药业有限公司 酶法拆分γ-内酰胺后副产物的处理方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO108347B1 (ro) * 1989-10-30 1994-04-28 Bellon Labor Sa Roger DERIVATI DE BENZO-(b)-NAFTIRIDIN-1,8 SI PROCEDEU DE PREPARARE A ACESTORA
GB9417249D0 (en) * 1994-08-26 1994-10-19 Wellcome Found A novel salt
JPH09291034A (ja) * 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
RU2174123C2 (ru) * 1996-10-28 2001-09-27 Новартис Аг Производные 8-арил-1,7-нафтиридина и фармацевтическая композиция, обладающая противовоспалительной активностью
US6312689B1 (en) * 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
FR2787790A1 (fr) * 1998-12-23 2000-06-30 Sanofi Sa Procede de preparation du (r)-(+)-3-{1[2-(4-benzoyl-2-(3,4- difluorophenyl)morpholin-2-yl)ethyl]-4-phenylpiperidin-4-yl} -1,1-dimethyluree, de ses sels, solvats et/ou hydrates
WO2000076512A1 (en) * 1999-06-11 2000-12-21 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
EP1318811B1 (en) 2000-08-17 2006-08-30 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
IL155371A0 (en) * 2000-11-28 2003-11-23 Pfizer Prod Inc Salts of a isothiazole-4-carboxamide and their use as anti-hyperproliferation agents
EP1461040B1 (en) * 2001-11-29 2006-03-15 Pfizer Products Inc. Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof
PL370858A1 (en) * 2001-12-12 2005-05-30 Pfizer Products Inc. Salt forms of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production
DE60322877D1 (de) * 2002-04-29 2008-09-25 Merck Sharp & Dohme Tetrahydropyranylcyclopentyltetrahydroisochino-linmodulatoren der chemokinrezeptoraktivität
JO2479B1 (en) 2002-04-29 2009-01-20 ميرك شارب اند دوم ليمتد Rates for the activity of the chemokine receptor of tetrahydrobranyl cycloneptil tetrahydrobredo predine
EP1501507B1 (en) * 2002-04-29 2008-05-28 Merck & Co., Inc. Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
AR045875A1 (es) * 2003-10-27 2005-11-16 Merck & Co Inc Procedimiento para la preparacion del antagonista ccr-2

Also Published As

Publication number Publication date
AU2004287416C1 (en) 2010-09-09
EP1682135A1 (en) 2006-07-26
RU2317295C1 (ru) 2008-02-20
EP1682135B1 (en) 2011-07-27
KR20060101476A (ko) 2006-09-25
ATE517622T1 (de) 2011-08-15
UA81365C2 (en) 2007-12-25
IS8400A (is) 2006-04-06
JP2007509940A (ja) 2007-04-19
AU2004287416B2 (en) 2009-11-19
ZA200602752B (en) 2007-08-29
EP1682135A4 (en) 2009-11-25
JP4542550B2 (ja) 2010-09-15
CN1870998B (zh) 2010-10-20
NO20062377L (no) 2006-05-24
CA2543201C (en) 2010-12-21
CO5690606A2 (es) 2006-10-31
MXPA06004647A (es) 2006-06-27
WO2005044264A1 (en) 2005-05-19
NZ546447A (en) 2009-02-28
IL175009A0 (en) 2006-08-20
US7473696B2 (en) 2009-01-06
ECSP066524A (es) 2006-10-10
US20070135474A1 (en) 2007-06-14
AU2004287416A1 (en) 2005-05-19
MA28104A1 (fr) 2006-08-01
CA2543201A1 (en) 2005-05-19
CN1870998A (zh) 2006-11-29

Similar Documents

Publication Publication Date Title
BRPI0415836A (pt) composto, métodos para a modulação da atividade de receptor de quimocina em um mamìfero, e para o tratamento, a melhoria, o controle ou a redução do risco de uma doença ou distúrbio inflamatório e imunorregulatório, e de artrite reumatóide, composição farmacêutica
PT1656345E (pt) Derivados cíclicos como moduladores da actividade de receptores de quimioquinas
TW200616632A (en) Compounds modulating c-kit activity and uses therefor
GEP20074210B (en) Tropane derivatives as ccr5 modulators
BR0309875A (pt) métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
EE200200217A (et) Asendatud indoolid NFkB aktiivsuse moduleerimiseks, nende valmistamismeetod ja kasutamine ning ravim ja selle valmistamismeetod
BR0309278A (pt) Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
TW200508224A (en) Cyclic derivatives as modulators of chemokine receptor activity
WO2006044334A3 (en) Platelet-derived growth factor compositions and methods of use thereof
MXPA02012712A (es) N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas.
PE20151249A1 (es) Derivados de pirazolopirimidina como inhibidores de jak quinasas
AU3126600A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU2003255819A1 (en) Pyrimidine derivatives as modulators of chemokine receptor activity
WO2004074450A8 (en) Combination therapy for treating protein deficiencies
BR0016164A (pt) Composto,composição farmacêutica, uso de um composto, e, métodos para o tratamento e/ou profilaxia de asma, alergia, artrite, incluindo artrite reumatóide e espondiloartrite, gota, ateroesclerose, doença intestinal inflamatória crÈnica (doença de crohn), distúrbios dermatológicos inflamatórios e proliferativos, psorìase, dermatite atópica, uveìte, choque séptico, aids e osteoporose e para o tratamento de acne
EP1617803A4 (en) USE OF MALONAMIDES AND DERIVATIVES THEREOF AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
WO2004060291A3 (en) Uses of mammalian cytokine; related reagents
WO2007011610A3 (en) Protein formulation for promoting hard tissue formation
AR045875A1 (es) Procedimiento para la preparacion del antagonista ccr-2
AU2003252025A1 (en) Compounds, compositions, and methods
BR0304963A (pt) Compostos, composição farmacêutica, e, métodos para modular a atividade de adenosina em um mamìfero, e para tratar um mamìfero sofrendo de ou suscetìvel às doenças
PT1730144E (pt) Compostos de 1,4,8-triaza-espiro[4.5]decan-2-ona substituídos
Prebet et al. Prolonged administration of azacitidine with or without entinostat increases rate of hematologic normalization for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup Trial E1905
EP1786815A4 (en) SPIRO COMPOUNDS AND METHOD FOR MODULATING CHEMOKIN RECEPTOR ACTIVITY
EA200700963A1 (ru) ТЕРАПЕВТИЧЕСКИЕ ПИРАЗОЛО[3,4-b]ПИРИДИНЫ И ИНДАЗОЛЫ

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

Free format text: ALTERADO DE: MERCK AND CO., INC.

B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/4375; C07D 471/04; A61P 19/02

Ipc: A61K 31/4375 (2011.01), C07D 471/04 (2011.01), A61

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.